Dr. Tomoki Sempokuya, MD

Dr. Sempokuya practices at St. Luke's Boise Medical Center in Boise, Idaho, part of St. Luke's Health System.

Dr. Sempokuya's NPI, 1013370725, was assigned on March 30, 2016. Dr. Sempokuya holds Hawaii license MD-20204.

Dr. Sempokuya's primary practice is St. Luke's Boise Medical Center, at 190 East Bannock Street, Boise, ID 83712 in Ada County. The practice phone is (208) 381-2222.

Dr. Sempokuya's primary practice is St. Luke's Boise Medical Center in Boise, Idaho, part of St. Luke's Health System. Dr. Sempokuya is also affiliated with Intermountain Medical Center. The medical group on file is St. Luke's Health System. Dmand AI also links Dr. Sempokuya to 3 more hospitals, 2 group practices and clinics, 2 medical groups and 1 breast imaging center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sempokuya practices, 8 sites in all. Vendor and product names are available with a free account.

Transplant hepatology is Dr. Sempokuya's primary specialty in the NPI Registry, under taxonomy code 207RT0003X. Dr. Sempokuya is licensed in Hawaii.

CMS data shows 443 Medicare services from Dr. Sempokuya across 6 procedure codes in 2024, for 151 Medicare patients. Medicare paid $40,708 for them.

CMS counts 151 Medicare patients who saw Dr. Sempokuya in 2024. The largest group is 65 to 74, with 79 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 11% are also on Medicaid. Their average risk score is 2.56, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Sempokuya's median patient age at 68, with 52% women.

In 2024, Dr. Sempokuya wrote 706 Medicare Part D claims for 148 patients. 90% of them were for generic drugs. CMS names the drug for 525 of them, across 16 drugs with 11 or more claims each, at $86,588 in total drug cost. In 2023, CMS named 46 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 97 out of 100 for Dr. Sempokuya for performance year 2024, reported through an alternative payment model (APM). Dr. Sempokuya accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Sempokuya as offering telehealth. CMS counts 14 procedures of upper gastrointestinal (gi) endoscopy for acid reflux by Dr. Sempokuya, more than 45% of the clinicians it reports for that procedure.

Colonoscopy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 28 papers to Dr. Sempokuya, published from 2011 to 2024. 2023 was the busiest year, with 5. The most frequent topics are Hawaii, Liver Neoplasms and SEER Program. Dr. Sempokuya has published most often in Hawaii J Health Soc Welf. Dr. Sempokuya's most frequent co-authors are Veeravich Jaruvongvanich, MD, Patompong Ungprasert, MD and Nicholas Michael McDonald, MD.

CMS Open Payments shows 132 general payments to Dr. Sempokuya from 23 drug and device companies from 2023 to 2025. Food and beverage make up the largest share, 100% of the total. Gilead Sciences, Inc. paid the most, $1,695.